Bergmann Anthony

Avg. Two Year Performance

(25%) Avg. Purchase Return

(12%) Compound

No sale track record

	1 Mo	3 Mo	6 Mo	1 Yr	2 Yr
Average Purchase Return	32%	48%	63%	35%	(25%)
Purchase Success Rate	1 of 1	1 of 1	1 of 1	1 of 1	0 of 1
Average Sale Return	--	--	--	--	--
Sale Success Rate	--	--	--	--	--

Nile Therapeutics, Inc

Drugs » Biotechnology

Chief Financial Officer:

Holdings: 2.38K shares

Sentiment

Avg. Two Year Performance

No purchase track record

No sale track record

Last Three Months:

0 Net Amount

Buy:	0	--
Sell:	0	--